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Orbitofrontal cortex (OFC) sulcogyral patterns are stable morphological variations established 
early in life. They consist of three distinct pattern types, with Type III in particular being 
associated with poor regulatory control (e.g., high sensation seeking and negative 
emotionality, low constraint), which may confer risk for earlier onset of cannabis (CB) use and 
greater use in later life. The OFC sulcogyral pattern may therefore be a stable trait marker in 
understanding individual differences in substance-use vulnerability and associated affective 
disturbances in users. In a large multisite cross-sectional study, we compared OFC pattern 
type distribution between 128 healthy controls (HC) and 146 CB users. Within users (n = 
140), we explored the association between OFC pattern type and CB use level, and 
subsequently if level of CB use informed by OFC pattern type may mediate disturbances in 
affective tone, as indexed by depressive symptoms. While OFC pattern distribution did not 
distinguish between HC and CB groups, it informed greater lifetime use within users. 
Specifically, CB users with pattern Type III in the right OFC tended to use more CB over their 
lifetime, than did CB users with pattern Type I or II. Greater lifetime CB use was subsequently 
associated with higher depressive symptoms, such that it mediated an indirect association 
between right OFC pattern Type III and higher depressive symptoms. The present study 
provides evidence for neurobiological differences, specifically sulcogyral pattern of the OFC, 
to modulate level of CB use, which may subsequently influence the expression of depressive 
symptoms.  
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Cannabis (CB) is a widely used psychoactive drug with a global estimate of 182 million users 
(United Nations Office on Drugs and Crime, 2015). Along with the high level of CB use across 
the world, there is a rising toll of treatment demand for CB use and its disorders (European 
Monitoring Centre for Drugs and Drug Addiction, 2016; United Nations Office on Drugs and 
Crime, 2015). Heavy CB use has been linked to affective disturbances such as depressive 
disorders (Degenhardt et al., 2003; Lev-Ran et al., 2014). Efforts to uncover the neural 
correlates of CB use have demonstrated morphological alterations across various brain 
regions including the hippocampus and the prefrontal cortex (Lorenzetti et al., 2016; Yücel et 
al., 2016). While neural abnormalities have often been interpreted as a consequence of CB 
use (Ashtari et al., 2011; Cousijn et al., 2012; Matochik et al., 2005; Yücel et al., 2008), 
premorbid structural differences may similarly confer vulnerability to develop heavier patterns 
of CB use (Jacobus et al., 2016; Pagliaccio et al., 2015) or affective disturbances (Amico et 
al., 2011). The understanding of such premorbid differences may inform knowledge on 
individual differences in substance use vulnerability, and the associated affective 
disturbances in users. 
 
It remains unclear whether (and which) neurobiological alterations predate cannabis 
use onset. Asides from prospective studies, this issue can be addressed via assessing 
neuroanatomy that is defined early in life and relatively stable to postnatal environmental 
factors such as substance use.  One such medium is the specific pattern of gyrification of the 
brain (White et al., 2010). Gyrification is the pattern of surface folding of the brain (White et 
al., 2010) that develops as early as 11 to 16 weeks gestation, and remains relatively stable 
from birth (Armstrong et al., 1995; Zilles et al., 1997). Importantly, early cortical folding 
forming particular sulcogyral patterns may reflect underlying connectivity or disrupted 
connectivity of the brain (Toro and Burnod, 2005; White et al., 2010). This provides a means 
for structure to inform function and behaviour, particularly in regions strongly implicated in 
substance use, such as the orbitofrontal cortex (OFC). Various studies have demonstrated 
reduced OFC volume (Battistella et al., 2014; Churchwell et al., 2010) and altered OFC 
function (functional connectivity in reward and inhibitory circuitry including the OFC) (Filbey 
and Dunlop, 2014; Filbey and Yezhuvath, 2013) in CB users. Pre-existing OFC morphological 
differences may also inform risk for later substance (i.e. alcohol, CB) use (Cheetham et al., 
2011; Kühn et al., 2015). These studies suggest OFC morphology may reflect vulnerabilities 
that inform future substance use behaviour. 
 
The sulcogyral pattern of the OFC in particular, is a viable trait marker to glean stable 
prenatal differences that may inform substance use behaviour. The OFC sulcogyral pattern 
has been categorised by Chiavaras and Petrides (2000), based on the continuity/discontinuity 
of the medial orbitofrontal sulcus (MOS) and the lateral orbitofrontal sulcus (LOS), into three 
basic types (Type I – discontinuity of the MOS; Type II – continuity of both the MOS and the 
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LOS; Type III – discontinuity of the LOS; Fig. 1). In a normative population, the distribution of 
the OFC sulcogyral pattern is skewed, with a predominance of Type I and an 
underrepresentation of Type III (Chiavaras and Petrides, 2000).  
 
 
Fig. 1 Examples of the three different orbitofrontal (OFC) sulcogyral pattern types, as traced 
on the coronal plane, and viewed on the transverse plane. Type I: rostral and caudal regions 
of the medial orbitofrontal sulci (MOSr and MOSc, red) are discontinuous, while the lateral 
orbitofrontal sulcus (LOS, purple) is continuous; Type II: both the MOS and LOS are 
continuous; Type III: the rostral and caudal regions of the MOSr and MOSc, as well as LOSr 
and LOSc are discontinuous. Also depicted are the intermediate orbital sulci (green and blue), 
and the transvers orbital sulci (TOS, yellow). Reproduced with permission from 
Bartholomeusz et al. (2013). 
 
However, altered pattern distribution has been associated with specific personality 
traits and presence of psychopathologies. In adolescents, a Type III pattern has been linked 
to greater ‘surgency’ (representing sensation-seeking and extraversion traits, and low levels 
of fear or shyness) (Whittle et al., 2014). Similarly in patients with schizophrenia, Type III 
pattern has been associated with temperaments (low ‘constraint’ and high ‘negative 
emotionality’) indicative of impulsivity, stress reaction, and proneness to anxiety and 
aggression (Nakamura et al., 2007), as well as poorer functioning (i.e. greater positive 
symptoms and lower socioeconomic status (Nakamura et al., 2007; Uehara-Aoyama et al., 
2011)). Patients with schizophrenia also show an altered proportion of sulcogyral pattern 
relative to controls (decreased proportion of Type I, and increased proportion of Type II and 
III) (Bartholomeusz et al., 2013; Chakirova et al., 2010; Cropley et al., 2015; Isomura et al., 
2017; Nakamura et al., 2008, 2007; Nishikawa et al., 2015; Takahashi et al., 2015; Uehara-
Aoyama et al., 2011). Overall, in both healthy and schizophrenia patient populations, Type III 
pattern is linked to personality traits reflecting poor regulatory control. Such traits may in turn 
confer risk for substance use, having been demonstrated to predict an earlier onset of 
substance use disorder, greater dependence, and greater lifetime CB use (Creemers et al., 
2010; Elkins et al., 2006; Krueger, 1999). Thus pre-existing OFC neuroanatomy, by reflecting 
underlying behavioural regulatory function, may be able to inform risk for later substance use. 
While the OFC volume has been demonstrated to predict CB use initiation in adolescents 
(Cheetham et al., 2011), no study has yet explored the OFC sulcogyral pattern in relation to 
CB use.  
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Regulatory deficits associated with altered OFC function may not only contribute to 
greater substance use, but also confer risk for affective disturbances (Diekhof et al., 2008; 
Drevets, 2007; Klimes-Dougan and Garber, 2016; Wagner et al., 2013a). Consistently, 
reduced OFC volume (Bremner et al., 2002; Lacerda et al., 2004) and altered functional 
connectivity between the OFC, dorsolateral prefrontal and anterior cingulate cortices (Frodl et 
al., 2010) have been observed in patients with depression. Importantly, regular CB use has 
also been associated with the emergence of affective disturbances including higher 
depressive symptoms (Crane et al., 2015) and an increased risk of developing depression 
(Lev-Ran et al., 2014). It is proposed that impaired OFC regulatory function and 
neuroanatomy underlies the concurrent development of CB use and depressive symptoms 
(Otten et al., 2010; Volkow and Fowler, 2000), via intensifying the strength of impulse and 
emotions (Beer et al., 2006; Wagner et al., 2013b). If specific OFC sulcogyral pattern types 
reflects distinct regulatory functions (Whittle et al., 2014), then these pattern type may inform 
later level of CB use and affective disturbances in CB users.  
 
In this study, we (i) compared the distribution of OFC pattern type between healthy 
controls (HC) and CB users to discern neural differences that may inform CB use; (ii) 
explored the association between OFC pattern type and CB use levels (i.e. three distinct 
measures including age of onset of regular use, current monthly use, and cumulative lifetime 
use) in CB users, to understand if potentially pre-existing OFC pattern type may inform later 
levels of CB use. We additionally (iii) explored whether higher levels of CB use will mediate a 
possible link between OFC pattern type and greater depressive symptoms, as guided by any 
significant association between OFC pattern type and specific CB use variables from analysis 
(ii). We hypothesised (i) OFC pattern distribution to be altered in CB users compared to HC; 
(ii) Type III pattern – linked to traits indicative of poor regulatory control – will be associated 
with higher CB use levels; and that (iii) CB users with Type III pattern would have greater 





We examined an aggregated sample of 128 HC and 146 regular CB users aged 17 to 55 
years, the data of which have been previously collected across four research sites including 
the University of Amsterdam (Amsterdam, N=76) (Cousijn et al., 2012), University of 
Barcelona (Barcelona, N=60) (Batalla et al., 2013), University of Wollongong (Wollongong, 
N=34) (Solowij et al., 2013), and Monash University (Melbourne, N=104) (Yücel et al., 2016). 
Informed written consent was obtained from all participants. All regular CB users had used 
CB at least two smoking days per month for a minimum of two months, and the majority of 
users smoked almost daily for a substantial period of time (duration of regular use, Mdn = 6 
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years, range = 0.5 – 38 years). Meanwhile, all HCs had minimal CB exposure (used less than 
50 times in their life, and did not use in last month). Exclusion criteria were: any history of 
chronic medical illness or neurological condition; use of psychoactive medications; any 
lifetime Axis I disorder according to the Diagnostic and Statistical Manual for Mental 
Disorders-Fourth Edition (other than nicotine use disorder, or cannabis use disorder for 
cannabis users); general MRI contraindications; regular use of other drugs (>50 times in the 
past 10 years) apart from cannabis, alcohol, and nicotine; and IQ<80. 
 
Measures 
Participants’ demographic, IQ level, depressive symptoms, and substance use levels 
(alcohol, tobacco, CB) were separately collected from each site using differing measures. We 
standardized these measures across sites. CB use levels measured include age of onset of 
regular use (defined as at least twice/month for at least two months), current monthly use, 
and cumulative lifetime use. CB users self-reported use in units familiar to them (e.g., joints, 
bongs, grams smoked), and use was then converted to cones, a standardised unit for 
comparison (e.g., 1 gram = 12 cones, and 1 paper joint = 3 cones; see standardised 
guidelines provided at https://cannabissupport.com.au/media/1593/timeline-followback.pdf). 
 
IQ was estimated using the Dutch version of the National Adult Reading Test (DART) 
(Schmand et al., 1991) (Amsterdam); the vocabulary subscale of the Wechsler Adult 
Intelligence Scale – Third Edition (WAIS-III) (Barcelona) (Wechsler, 1997); the National Adult 
Reading Test (NART) (Wollongong) (Nelson, 1982); and the Wechsler Abbreviated Scale of 
Intelligence (WASI) (Melbourne) (Wechsler, 1999). The vocabulary subscale score from the 
Barcelona site was converted to an estimated full scale IQ by standardising to the mean and 
standard deviation of the average IQ of CB and HC respectively of the three other sites. 
Depressive symptoms were obtained using the Beck Depression Inventory (BDI) 
(Amsterdam, Barcelona, Melbourne) (Beck et al., 1961) and Hamilton Depression Rating 
Scale (HAMD) (Wollongong) (Hamilton, 1960). Depressive symptom scores from each site 
were standardised, using previously reported population norms for each scale as the mean by 
which obtained depressive symptom scores were converted to a z-score (Crawford et al., 
2011; Zimmerman et al., 2004). 
 
Structural Image Processing 
T1-weighted structural MR images were independently acquired at each imaging site. 
Scanner details are documented in the Supplementary Table 1, and by the original research 
groups (Batalla et al., 2013; Cousijn et al., 2012; Yücel et al., 2016, 2008). MR image were 
preprocessed using FreeSurfer image analysis (http://surfer.nmr.mgh.harvard.edu/) version 
5.3.0 to correct for intensity non-uniformity artifacts (Sled et al., 1998; Zheng et al., 2009). 
The intensity of the subsequent MR images was then standardised between sites - based on 
the average grey matter, white matter, and cerebrospinal fluid intensity from each site, using 
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the FMRIB Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl/), to ensure consistency 
across sites for subsequent manual tracing. Finally, MR images were visually inspected and 
reoriented along the anterior commissure-posterior commissure (AC-PC) plane only if they 
deviated from the plane by more than 0.1 radian. 
 
OFC sulcogyral pattern classification 
The OFC sulcogyral pattern types were classified for each MR image using the visualisation 
and analysis software Analyze 12.0 (AnalyzeDirect, Overland Park, KS), based on the 
continuity/discontinuity of the MOS and LOS between the rostral and caudal regions 
(Chiavaras and Petrides, 2000). In Type I, the MOS was disconnected while the LOS was 
intact. In Type II, both the MOS and LOS were intact. For Type III, both the MOS and LOS 
were disconnected. In rare cases where LOS was disconnected but MOS was intact (n = 27; 
classified as Type IV in some papers (Chakirova et al., 2010)), we classified the OFC pattern 
as Type III, in accordance with the method used by (Bartholomeusz et al., 2013). 
 
All sulci appearing on the orbital surface were traced in the coronal plane slice-by-
slice, and identified on the transverse plane. A fissure was considered a sulcus if it was 
visible in at least four coronal and four transverse slices. A sulcus was considered continuous 
with another sulcus if they were clearly connected in at least three slices. OFC pattern 
classification was performed by Y.C. while blinded to gender, group, and imaging site. Intra- 
and inter-rater reliability (interclass correlation coefficient, ICC) performed by Y.C., C.F.B., 
and E.P.G., on 20 randomly selected brains from the Melbourne Neuropsychiatry Centre 
(University of Melbourne, Department of Psychiatry) database, were 0.90 and 0.75 
respectively. All ambiguous classifications identified in the current sample (i.e. 14% of the 
total sample) were reviewed by C.F.B. and consensus reached. To further ensure Y.C.’s 
classification validity, a subset of 20 randomly selected brains (5 from each imaging site) that 
were not reviewed by C.B., from the current sample, were also reviewed by E.P.G. 
Consensus between Y.C. and E.P.G. was high at a level of 92.5%. 
 
Statistical Analyses 
Group differences between HC and CB users for variables including age, IQ, depressive 
symptoms, alcohol, and tobacco use were assessed using independent-samples t-test; while 
group differences for gender were assessed via Pearson’s χ2 statistics. To ensure that OFC 
pattern distribution was not related to imaging site, countries, or continents, we ran separate 
Pearson’s χ2 statistics for HC and CB users, comparing left and right OFC pattern across 
sites, and across continents. We also compared left and right OFC pattern distribution by age, 
gender, IQ, depressive symptoms, alcohol and tobacco use to assess and rule out any 
demographic confounder.  
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To discern putative pre-existing neural differences in CB users relative to HC in OFC 
sulcogyral pattern distribution (separately for right and left hemisphere) we ran χ2 statistics. 
Subsequently to understand the link between OFC sulcogyral pattern and CB use levels in 
CB users only, we performed a series of three separate ANCOVAs to explore whether OFC 
pattern affected three distinct measures of CB use levels (i.e., age of onset of regular use, 
current monthly use, and cumulative lifetime use). Fixed factors included left and right OFC 
patterns, dependent variables included one of the three measures of CB use level, and the 
remaining two measures of CB use levels were used as covariates. We corrected for multiple 
comparisons (i.e. three comparisons corresponding to three CB use measures) using 
Benjamini and Yekutieli’s modified false discovery rate (FDR) method (Benjamini and 
Yekutieli, 2001). 
 
Finally, to explore the role of higher CB use level as a mediator between specific 
OFC pattern type and greater depressive symptoms, we ran post-hoc analyses with the 
significant CB use variable emerging from the ANCOVA results, in a mediation model. CB 
use level is adopted as a mediator between OFC pattern types (categorical factor) and 
depressive symptoms. The mediation model was tested using the Hayes PROCESS macro 
(2.16.2), instead of the causal step approach (wherein each path of the model is ascertained 
separately), due to criticisms of the latter approach (Hayes, 2016, 2013, 2009). Indirect effect 





Sample data and OFC pattern distribution of HC and CB users are presented in Table 1. HC 
and CB users were matched by age, gender, and alcohol use level. CB users had a 
significantly lower IQ (p < .001), greater depressive symptoms (p < .001), and used more 
cigarettes per month (p < .001) than HC. Further sample characteristics by imaging site are 
provided in Supplementary Table 2.  
 
Table 1 Overview of Demographic, IQ, Substance Use Levels (Mean (SD)), and Orbitofrontal 
Cortex (OFC) Pattern Distribution (n (%)) of Healthy Controls (HC) and Cannabis (CB) Users  
 HC  c 
N = 128 
CB c 
N = 146 
N t/χ2 p 
Age 26.25 (8.86) 28.41 (10.51) 274 1.84 .07 
Gender (% M / F) 71.09/28.91 67.12/32.88 274 0.50 .51 
IQ a 109.26 (10.43) 103.58 (10.67) 270 -4.41 <.001** 
Depressive Symptoms b -0.41 (0.65) 0.26 (1.19) 267 5.56 <.001** 
Alcohol (StDr/mth) c 19.71 (23.63) 24.55 (25.13) 264 1.61 .11 
Tobacco (Cig/mth) c 29.89 (96.49) 258.01 (236.04) 267 10.56 <.001** 
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Cannabis Use      
   Onset Regular Use (years) - 17.85 (3.37) 141   
   Current Use (cones/month) - 339.59 (322.90) 143   
   Lifetime Use (cones) - 58,164.51 
(99,182.44) 
144   
Right OFC c sulcogyral pattern, n (%)  1.06 .59 
   Type I 63 (49) 69 (47)    
   Type II 21 (16) 31 (21)    
   Type III 44 (34) 46 (32)    
Left OFC sulcogyral pattern, n (%)  0.30 .86 
   Type I 64 (50) 70 (48)    
   Type II 25 (20) 27 (18)    
   Type III 39 (30) 49 (34)    
a Estimated IQ measured with the Dutch version of the National Adult Reading Test (DART; Amsterdam) 
(Schmand et al., 1991), the vocabulary subscale of the Wechsler Adult Intelligence Scale – Third Edition 
(WAIS-III; Barcelona) (Wechsler, 1997); the National Adult Reading Test (NART; Wollongong) (Nelson, 
1982), and the Wechsler Abbreviated Scale of Intelligence (WASI; Melbourne) (Wechsler, 1999).  
b Depressive symptoms measured with the Beck Depression Inventory (BDI; Amsterdam, Barcelona, 
Melbourne) (Beck et al., 1961) and Hamilton Depression Rating Scale (HAMD; Wollongong) (Hamilton, 
1960); and subsequently standardized to a z-score based on reported population means (Crawford et 
al., 2011; Zimmerman et al., 2004). 
c StDr/mth = standard drinks per month; Cig/mth = cigarettes smoked per month; OFC = orbitofrontal 
cortex; HC = healthy controls; CB = cannabis users 
**p<.001 
 
Prior to the main analysis, χ2 tests within each of HC and CB groups, examined 
across imaging sites, within and across continents, suggested no significant differences in 
OFC pattern distribution associated with imaging site, and within or across continents 
(Supplementary Table 3). Nor did OFC pattern distribution differ significantly by gender, IQ, 
and demographic variables in the right and left hemispheres (Table 2). Therefore we did not 
include any of these variables as factors in any further analyses. 
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Table 2 Comparison of Differences in Orbitofrontal Cortex (OFC) Pattern Distribution in All Participants by Demographic, IQ, and Cannabis Use Levels 
Right Hemisphere Type I 
N = 132 
Type II 
N = 52 
Type III 
N = 90 
N F/χ2 p 
Age 26.90 (9.86) 26.34 (8.48) 28.75 (10.40) 274 1.41 .25 
Gender (% M / F) 69.70/30.30 69.20/30.80 67.80/32.20 274 0.09 .95 
IQ a 106.58 (11.74) 104.91 (8.85) 106.52 (10.75) 270 0.54 .58 
Depressive Symptoms b -0.04 (1.07) -0.11 (0.84) -0.02 (1.09) 267 0.16 .85 
Alcohol (StDr/mth) c 22.88 (26.32) 22.72 (25.26) 21.14 (21.22) 264 0.29 .87 
Tobacco (Cig/mth) c 161.53 (221.55) 127.19 (207.63) 172.48 (236.13) 267 0.47 .63 
Cannabis Use d Type I 
N = 67 
Type II 
N = 28 
Type III 
N = 45 
N F p 
   Onset Regular Use (years) 17.73 (3.09) 18.16 (4.05) 17.84 (3.41) 140 0.15 .86 
   Current Use (cones/month) 371.73 (402.87) 280.48 (216.76) 327.46 (243.54) 140 2.31 .10 
   Lifetime Use (cones) 49,392.85 (70,590.47) 38,737.82 (45,936.98) 73,538.91 (89,776.01) 140 3.91 .02* 
Left Hemisphere Type I 
N = 134 
Type II  
N = 52 
Type III 
N = 88 
N F/χ2 p 
Age 27.05 (9.59) 25.97 (8.71) 28.78 (10.66) 274 1.61 .20 
Gender (% M / F) 64.90/35.10 73.10/26.90 72.70/27.30 274 2.02 .37 
IQ a 105.62 (11.81) 105.94 (10.32) 107.39 (9.82) 270 0.79 .45 
Depressive Symptoms b -0.08 (0.97) -0.05 (1.08) -0.01 (1.11) 267 0.16 .86 
Alcohol (StDr/mth) c 22.23 (23.38) 24.44 (27.41) 21.14 (24.61) 264 0.29 .75 
Tobacco (Cig/mth) c 149.63 (207.43) 138.73 (208.58) 160.74 (235.55) 267 0.18 .83 
Cannabis Use d Type I Type II Type III N F p 
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N = 67 N = 26 N = 47 
   Onset Regular Use (years) 17.78 (3.50) 18.14 (2.84) 17.80 (3.55) 140 0.11 .90 
   Current Use (cones/month) 323.48 (244.38) 319.04 (345.98) 372.92 (410.44) 140 0.09 .92 
   Lifetime Use (cones) 53,420.97 (74,265.86) 40,971.54 (54,277.86) 65,080.13 (83,109.55) 140 0.67 .51 
a Estimated IQ measured with the Dutch version of the National Adult Reading Test (DART; Amsterdam) (Schmand et al., 1991), the vocabulary subscale of the Wechsler Adult 
Intelligence Scale – Third Edition (WAIS-III; Barcelona) (Wechsler, 1997); the National Adult Reading Test (NART; Wollongong) (Nelson, 1982), and the Wechsler Abbreviated 
Scale of Intelligence (WASI; Melbourne) (Wechsler, 1999).  
b Depressive symptoms measured with the Beck Depression Inventory (BDI; Amsterdam, Barcelona, Melbourne) (Beck et al., 1961) and Hamilton Depression Rating Scale 
(HAMD; Wollongong) (Hamilton, 1960); and subsequently standardized to a z-score based on reported population means (Crawford et al., 2011; Zimmerman et al., 2004). 
c StDr/mth = standard drinks per month; Cig/mth = cigarettes smoked per month 
d ANCOVA on cannabis use level in cannabis users only, with right and left hemisphere OFC pattern as fixed factors, and the other two CB use levels as covariates. 
Cumulative lifetime CB use of two users has been winsorised to reduce their influence (864,000 and 459,000 respectively replaced with 355,712 and 356,704, i.e., 3.00 and 




OFC pattern type distribution across groups – HC vs. CB 
χ2 tests of OFC pattern distribution between HC and CB users, indicated that both groups did 
not differ significantly in right (χ2(2) = 1.06, p = .59) or left (χ2(2) = 0.30, p = .86) OFC pattern 
distribution.  
 
OFC pattern association with level of CB use 
To discern the association between OFC pattern type and level of CB use, three separate 
ANCOVAs were performed (i.e. one each for CB use levels – age of onset of regular use, 
current monthly use, and cumulative lifetime use). As CB use levels were strongly correlated 
(range of r = -.301 – .622, p < .001), the remaining two CB use levels were used as 
covariates in all three ANCOVA analyses. For this analysis, six CB users (all males) were 
excluded from the original sample due to missing CB use levels, resulting in a final sample of 
140 CB users1. Cumulative lifetime CB use of two users was winsorised to reduce their 
influence (864,000 and 459,000 respectively replaced with 355,712 and 356,704, i.e., 3.00 
and 3.01 standard deviations above the mean). IQ and tobacco use, while differing between 
HC and CB users, were not adopted as covariates, as they were not significantly related to 
OFC pattern type (Table 2), nor did they affect the association between OFC pattern type and 
level of CB use as covariates in the subsequent analysis. 
 
ANCOVA with right and left OFC pattern as fixed factor show that the right OFC 
pattern was significantly associated with cumulative lifetime use (Table 2; F2,133 = 3.91, p = 
.022, ηp2 = .055)2. After false discovery rate (FDR) correction (B-Y method (Benjamini and 
Yekutieli, 2001), critical value = .02) the strength of this association was reduced to trend-
level. We observed that those CB users with right OFC Type III pattern had higher cumulative 
lifetime use (M = 73,539, SD = 89,776) than those with Type I (M = 49,393, SD = 70,590, p = 
.010, 95% CI [7314, 52249]) or Type II (M = 38,738, SD = 45,937, p = .039, 95% CI [1499, 
57799]), controlling for age of onset of regular use and current monthly use (Fig. 2). We 
therefore adopted cumulative lifetime CB use as a mediator in the subsequent mediation 
model between OFC pattern type and depressive symptoms. No other significant association 
was found. 
 
                                                        
1 The six excluded CB users did not differ in age (M = 26.33, SD = 11.91, n = 6; t(144) = -
0.49, p = .62), IQ (M = 103.58, SD = 9.20, n = 5; t(141) = 0.00, p = 1.00), alcohol use (M = 
22.40, SD = 18.08, n = 5; t(139) = 0.20, p = .85), and tobacco use (M = 92.00, SD = 141.19, n 
= 4; t(140) = 1.43, p = .15) from non-excluded CB users. Nor did they differ significantly in 
OFC sulcogyral pattern type distribution (n of Type I:II:III = 2:3:1, χ2(2) = 3.13, p = .21; and n 
of Type I:II:III = 3:1:2, χ2(2) = 0.02, p = .99 for the right and left hemispheres respectively) 
from the non-excluded CB users. However they did report lower depressive symptoms (M = -
.80, SD = 0.15, n = 6; t(142) = 2.27, p = .03) than non-excluded CB users. 
2 ANCOVA with unwinsorised data suggest however that results no longer hold (F2,133 = 2.22, 
p = 0.11, ηp2 = .032). 
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Fig. 2 Cumulative lifetime use in cannabis (CB) users by right orbitofrontal cortex (OFC) 
pattern type, * p < .05. Error bars represent 95% confidence interval. 
 
Lifetime CB use as mediator between OFC pattern and depressive symptoms 
Given the higher incidence of depressive symptoms in our sample of CB users compared to 
HC, and the OFC’s role in the manifestation of affective dysregulation in substance 
dependence (Diekhof et al., 2008), we explored cumulative lifetime CB use as a mediator 
between right OFC Type III pattern and depressive symptoms. The right OFC Type III pattern 
was modeled as a categorical variable (i.e. presence versus absence of Type III). Covariates 
included current monthly CB use and age of onset of regular use, which did and did not 
significantly affect the model, respectively.  
 
Within CB users, having a right OFC Type III pattern was not directly associated with 
depressive symptoms. However, as shown in Fig. 3, right OFC Type III pattern was indirectly 
associated with higher depressive symptoms, through greater amount of lifetime CB use (b = 
0.14, 95% CI [0.04, 0.30])3. Given the significant difference between HC and CB users in IQ 
and tobacco use level, we further conducted a second mediation analysis with lifetime CB 
use, IQ, and tobacco use as joint mediators to rule out the influence of these confounders on 
the model (Supplementary Figure 1). Both IQ and tobacco use were not significant mediators 
of the model, and they did not significantly influence the association between right OFC Type 
III, lifetime CB use, and depressive symptoms. 
                                                        




Fig. 3 Cumulative lifetime cannabis (CB) use as mediator between right orbitofrontal cortex 
(OFC) pattern type (categorical, Type III vs. non-Type III) and depressive symptoms in CB 
users; indirect effect, b = 0.14, 95% CI = [0.04, 0.30]. 
 
Discussion 
Our study was the first to investigate OFC sulcogyral pattern – largely determined by birth 
(Chi et al., 1977) and measured via a validated classification method (Bartholomeusz et al., 
2013; Chiavaras and Petrides, 2000) – in relation to CB use, CB use levels and associated 
depressive symptoms. We found no significant differences between the CB and HC groups, 
in contrast with our first hypothesis. However, those CB users with right OFC Type III pattern 
(relative to Type I and II) had higher cumulative lifetime CB use; and cumulative use in turn 
mediated an indirect association between right OFC Type III pattern and higher depressive 
symptoms. Our findings support the hypothesis that specific OFC gyrification patterns (i.e. 
Type III pattern) are associated with greater lifetime cannabis use, and are furthermore 
consistent with previous studies demonstrating greater CB use to be associated with higher 
depressive symptoms (Crane et al., 2015). In sum, OFC pattern type did not contribute to the 
risk of becoming a CB user, but had an impact on individuals who became CB users, by 
predisposing them to greater levels of use throughout their lifetime. These users with greater 
levels of lifetime CB use may subsequently experience greater depressive symptoms.  
 
Our findings suggest that Type III pattern in the right hemisphere may predispose 
individuals to greater levels of CB use. This may occur via the altered emotional and cognitive 
features associated with Type III pattern – such as poor regulatory control, including higher 
negative emotionality, impulsivity, and stress reactivity (Nakamura et al., 2007; Whittle et al., 
2014). The OFC function is relevant to regulatory control as it is involved in monitoring and 
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processing motivational information, therefore supporting context-appropriate behaviour 
(Diekhof et al., 2008; Kringelbach and Rolls, 2004; Tremblay and Schultz, 1999). Impaired 
regulatory function of the OFC could thus manifest as a maladaptively intense drive to 
procure substances, facilitating greater and more compulsive substance-seeking (Volkow and 
Fowler, 2000). Indeed, the temperamental variables linked to Type III pattern (e.g. higher 
negative emotionality, impulsivity, stress reactivity, and sensation-seeking (Nakamura et al., 
2007; Whittle et al., 2014)) have been associated with CB use – increased use frequency and 
risk of lifetime use (Creemers et al., 2010, 2009). Nevertheless, future studies will be 
necessary to substantiate the link between OFC neuroanatomy, temperamental variables of 
behaviour regulation, and substance use. 
 
In our exploratory analyses, we further showed that higher lifetime CB use is 
associated with higher depressive symptoms, thus mediating an indirect association between 
Type III pattern and greater depressive symptoms. This is consistent with previous evidence 
linking heavy CB use and depressive symptoms (Crane et al., 2015) or risk of developing 
depressive disorders (Lev-Ran et al., 2014). We suggest that the Type III pattern may reflect 
poor regulatory control, which underlies the greater level of CB use, and in turn higher CB-
use-related depressive symptoms in users. In substantiation of our claim, CB use and greater 
depressive symptoms have been demonstrated to co-occur in adolescents with low levels of 
self-control (Otten et al., 2010). Additionally in a study of abstinent substance-dependent 
users, measures of self-regulation and emotional functioning were directly correlated 
(Verdejo-García et al., 2007), suggesting regulatory control to be relevant to the manifestation 
of emotional disturbances such as depressive symptoms. Unfortunately, as we do not have a 
direct measure of ‘regulatory control’, we are unable to examine the contribution of this trait 
behaviour in both OFC pattern and related psychopathologies. Our findings contrast 
previously reported association between right OFC Type I pattern (not Type III) and higher 
depressive symptoms in a community sample of non-CB-using adolescents (Whittle et al., 
2014). This may reflect the specific interaction between CB use and pattern type on emerging 
depressive symptoms, with higher depressive symptoms in CB users with OFC Type III 
pattern manifesting as a result of prolonged high levels of use. However in our sample of 
HCs, we did not find any association between OFC pattern type and depressive symptoms 
either (analysis not shown, p = .67 and p = .77 for left and right hemisphere respectively). We 
speculate our lack of finding to be due to the age difference between our adult sample and 
Whittle and colleague’s (2014) adolescent sample, as emotional regulation may develop with 
age (McRae et al., 2012).  
 
It is noteworthy that the association we found between lifetime CB use and OFC 
pattern was confined to the right hemisphere. The right hemisphere is suggested to be 
specialised for socioemotional functioning and emotion management (Borod 1992; Schore 
2001; Tranel et al. 2002). Greater right over left frontal activation has also been linked to 
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greater negative affective response and difficulties with affective regulation, that may be 
related to both internalising (e.g. anxious behavior) and externalising (e.g. aggressive 
behaviour) problems (Wheeler et al. 1993; Fox et al. 1996). An overwhelming percentage of 
studies investigating OFC pattern type have found evidence linking pattern Type III and 
psychopathology in the right hemisphere (Chakirova et al. 2010; Takayanagi et al. 2010; 
Bartholomeusz et al. 2013). Overall, our study along with the examples above contribute to 
evidence of the lateralisation of OFC function (Happaney et al. 2004), possibly related to 
asymmetry in the timeline and functional specialization of cortical development (Toga & 
Thompson 2003). 
 
The OFC classification method used in this study is both valid and reliable, and 
minimally affected by confounders including gender differences and imaging sites. In support 
of the reliability of our OFC classification, the percentage distribution of OFC pattern found in 
our sample (Type I:II:III = 49:19:32%) was similar to that of previously examined samples of 
healthy controls (aggregated means of Type I:II:III = 60:19:20%; χ2(2) = 4.32, p = .12) 
(Bartholomeusz et al., 2013; Chakirova et al., 2010; Chiavaras and Petrides, 2000; Cropley et 
al., 2015; Ganella et al., 2015; Isomura et al., 2017; Lavoie et al., 2014; Nakamura et al., 
2007; Nishikawa et al., 2015; Takahashi et al., 2014, 2015; Takayanagi et al., 2010; Uehara-
Aoyama et al., 2011; Watanabe et al., 2014; Whittle et al., 2014). We also did not find any 
gender-related differences in OFC pattern distribution, consistent with most previous studies 
(Uehara-Aoyama et al., 2011; Whittle et al., 2014). Finally, we did not observe any imaging 
site related differences, which points to the reliability of OFC pattern classification across 
different scanners in our sample. While there is no single conclusive study on the stability of 
the OFC pattern across countries and population, it nevertheless appears to be a potentially 
stable morphological trait marker, useful for understanding temperament, behaviour, and 
psychopathology. 
 
We acknowledge some limitations of our study. Firstly, while we propose self-
regulatory deficits related to OFC Type III pattern to predispose CB users to greater levels of 
use, we did not have measures of behavioural self-regulation. As such, we were unable to 
examine the relationship between behavioural regulation and OFC pattern type. This may 
represent a possible future avenue for investigation. Second, depressive symptoms were only 
assessed cross-sectionally at the time of assessment. Therefore we cannot discern to what 
extent depressive symptoms precipitated CB use, and whether OFC pattern may have 
informed depressive symptoms prior to CB initiation. We also did not examine other 
measures of affective disturbances such as anxiety, in relation to CB use.  We adopted 
depressive (rather than anxiety) symptoms as an index of affective disturbance due to the link 
between CB use and subsequent depressive symptoms (Degenhardt et al., 2003), and on 
grounds of anxiety symptoms possibly precipitating rather than being a consequence of CB 
use (Stapinski et al., 2016). Furthermore, not all imaging sites collected information on 
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anxiety symptoms. Future longitudinal studies will be necessary to fully explore whether OFC 
pattern is associated with differences in depressive and anxiety symptoms prior to CB use, or 
whether such outcomes arose as a result of continual CB exposure. Additionally, as genetic 
factors may affect cortical folding patterns (Atkinson et al., 2015), genetic or epigenetic 
factors guiding early neurodevelopment may present as more robust biomarkers of CB use 
level (Agrawal and Lynskey, 2006; Ystrom et al., 2014), as compared to OFC sulcogyral 
pattern. Multifactorial models integrating genetic, neurobiological, and behavioural factors will 
be necessary to provide a more complete account of the causal influences on CB use. 
Finally, we did not find any association between OFC pattern and alcohol or tobacco use. The 
specificity of the association between OFC pattern and greater lifetime CB use, rather than 
other substance (alcohol and tobacco) use may be due to the fact that alcohol and tobacco 
use were quantified as ‘monthly use’ in our study, rather than ‘cumulative use’. Indeed, we 
also found no association with current monthly CB use. Given that short-term measures of 
use (i.e. monthly, compared to lifetime use) may fluctuate with situational changes, these may 
be less reliably associated with stable trait markers such as OFC pattern. However, further 
clarification in users of other substances (e.g. alcohol, tobacco) will be necessary. 
 
Conclusion 
In conclusion, while there was no particular OFC pattern Type that conferred risk for CB use 
versus non-use, OFC Type III pattern in the right hemisphere was associated with greater 
lifetime use in CB users. Greater lifetime CB use was in turn associated with greater 
depressive symptoms in CB users. Future longitudinal work is needed to ascertain the extent 
to which OFC pattern informs pre-existing temperamental features that may contribute 
towards substance use. Meanwhile, comprehensive examination and integration of various 
factors including genetic, ethnic, and prenatal factors might provide insight regarding the 
moderators of OFC pattern distribution across populations. This may in turn support the use 
of OFC pattern type as a stable trait marker to further understand pre-existing vulnerabilities 
that influence substance use level among CB and/or other substance users, and mental 





The authors assert that all procedures contributing to this work comply with the ethical 
standards of the relevant national and institutional committees on human experimentation and 
with the Helsinki Declaration of 1975, as revised in 2008.  
 
Conflict of interest 
None. 
 
Financial support and acknowledgement 
Original data collection was supported by the Netherlands Organisation for Scientific 
Research–Health Research and Development, ZON-Mw [AG, grant #31180002]; an 
Amsterdam Brain Imaging Platform grant [JC]; Plan Nacional sobre Drogas. Ministerio de 
Sanidad y Política Social [RMS, grant PNSD:2011/050 and SGR:2014/1114]; the Clive and 
Vera Ramaciotti Foundation for Biomedical Research [NS]; the Schizophrenia Research 
Institute with NSW Health [NS]; and the National Health and Medical Research Council 
(NHMRC) of Australia Project Grant [NS, #459111]. 
 
MY was supported by a National Health and Medical Research Council of Australia 
Fellowship [App#1117188] and the David Winston Turner Endowment Fund. EPG was 
supported by the University of Melbourne and CRC for Mental Health PhD top-up scholarship. 
 
Author contribution 
VL and MY designed the study; NS, MY, AB, JC, AEG, RMS, SW, and VL collected the data; 
YC, AEG, and CB contributed to the data analysis and interpretation; YC wrote the 
manuscript, while CB, VL, NS, and CS provided critical revision to the manuscript. All authors 
have approved the final article. 
 19 
References 
Agrawal, A., Lynskey, M.T., 2006. The genetic epidemiology of cannabis use, abuse and 
dependence. Addiction 101, 801–812. 
Amico, F.., Meisenzahl, E.., Koutsouleris, N.., Reiser, M.., Möller, H.-J.., Frodl, T.., 2011. 
Structural MRI correlates for vulnerability and resilience to major depressive disorder. J. 
Psychiatry Neurosci. 36, 15–22.  
Armstrong, E., Schleicher,  a, Omran, H., Curtis, M., Zilles, K., 1995. The ontogeny of human 
gyrification. Cereb. Cortex 5, 56–63. 
Ashtari, M., Avants, B., Cyckowski, L., Cervellione, K.L., Roofeh, D., Cook, P., Gee, J., Sevy, 
S., Kumra, S., 2011. Medial temporal structures and memory functions in adolescents 
with heavy cannabis use. J. Psychiatr. Res. 45, 1055–1066.  
Atkinson, E.G., Rogers, J., Mahaney, M.C., Cox, L.A., Cheverud, J.M., 2015. Cortical folding 
of the primate brain: An interdisciplinary examination of the genetic architecture, 
modularity, and evolvability of a significant neurological trait in pedigreed baboons 
(genus papio). Genetics 200, 651–665.  
Bartholomeusz, C.F., Whittle, S.L., Montague, A., Ansell, B., McGorry, P.D., Velakoulis, D., 
Pantelis, C., Wood, S.J., 2013. Sulcogyral patterns and morphological abnormalities of 
the orbitofrontal cortex in psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry 44, 
168–77. 
Batalla, A., Soriano-mas, C., López-solà, M., Torrens, M., Crippa, J.A., Bhattacharyya, S., 
Blanco-hinojo, L., Fagundo, A.B., Harrison, B.J., Nogué, S., Torre, R. De, Farré, M., 
Pujol, J., Martín-santos, R., 2013. Modulation of brain structure by catechol-O-
methyltransferase Val158Met polymorphism in chronic cannabis users. Addict. Biol. 19, 
722–732.  
Battistella, G., Fornari, E., Annoni, J.-M., Chtioui, H., Dao, K., Fabritius, M., Favrat, B., Mall, 
J.-F., Maeder, P., Giroud, C., 2014. Long-Term Effects of Cannabis on Brain Structure. 
Neuropsychopharmacology 39, 2041–2048. 
Beck, A.T., Ward, C.H., Mendelson, M.M., Mock, J.J., Erbaugh, J., 1961. An inventory for 
measuring depression. Arch. Gen. Psychiatry 4, 561–571. 
Beer, J.S., John, O.P., Scabini, D., Knight, R.T., 2006. Orbitofrontal cortex and social 
behavior: integrating self-monitoring and emotion-cognition interactions. J. Cogn. 
Neurosci. 18, 871–9. 
Benjamini, Y., Yekutieli, D., 2001. The control of the false discovery rate in multiple testing 
under depencency. Ann. Stat. 29, 1165–1188.  
Bremner, J.D., Vythilingam, M., Vermetten, E., Nazeer, A., Adil, J., Khan, S., Staib, L.H., 
Charney, D.S., 2002. Reduced volume of orbitofrontal cortex in major depression. Biol. 
Psychiatry 51, 273–279. 
Chakirova, G., Welch, K.A., Moorhead, T.W.J., Stanfield, A.C., Hall, J.A., Skehel, P., Brown, 
V.J., Johnstone, E.C., Owens, D.G.C., Lawrie, S.M., McIntosh, A.M., 2010. Orbitofrontal 
morphology in people at high risk of developing schizophrenia. Eur. Psychiatry 25, 366–
 20 
372. 
Cheetham, A., Allen, N.B., Whittle, S., Simmons, J.G., Yücel, M., Lubman, D.I., 2011. 
Orbitofrontal volumes in early adolescence predict initiation of cannabis use : A 4-year 
longitudinal and prospective study. Biol. Psychiatry 71, 684–692.  
Chi, J.G., Dooling, E.C., Gilles, F.H., 1977. Gyral development of the human brain. Ann. 
Neurol. 1, 86–93. 
Chiavaras, M.M., Petrides, M., 2000. Orbitofrontal sulci of the human and macaque monkey 
brain. J. Comp. Neurol. 422, 35–54.  
Churchwell, J.C., Lopez-Larson, M., Yurgelun-Todd, D.A., 2010. Altered frontal cortical 
volume and decision making in adolescent cannabis users. Front. Psychol. 1, 1–8. 
Cousijn, J., Wiers, R.W., Ridderinkhof, K.R., Brink, W. Van Den, Veltman, D.J., Goudriaan, 
A.E., 2012. Grey matter alterations associated with cannabis use : Results of a VBM 
study in heavy cannabis users and healthy controls. Neuroimage 59, 3845–3851.  
Crane, N.A., Langenecker, S.A., Mermelstein, R.J., 2015. Gender differences in the 
associations among marijuana use, cigarette use, and symptoms of depression during 
adolescence and young adulthood. Addict. Behav. 49, 33–39.  
Crawford, J., Cayley, C., Lovibond, P.F., Wilson, P.H., Hartley, C., 2011. Percentile norms 
and accompanying interval estimates from an Australian general adult population 
sample for self-report mood scales (BAI, BDI, CRSD, CES-D, DASS, DASS-21, STAI-X, 
STAI-Y, SRDS, and SRAS). Aust. Psychol. 46, 3–14.  
Creemers, H.E., Dijkstra, J.K., Vollebergh, W.A.M., Ormel, J., Verhulst, F.C., Huizink, A.C., 
2010. Predicting life-time and regular cannabis use during adolescence; The roles of 
temperament and peer substance use: The TRAILS study. Addiction 105, 699–708.  
Creemers, H.E., Verhulst, F.C., Huizink, A.C., 2009. Temperamental risk factors for 
adolescent cannabis use: a systematic review of prospective general population studies. 
Subst. Use Misuse 44, 1833–1854.  
Cropley, V.L., Bartholomeusz, C.F., Wu, P., Wood, S.J., Proffitt, T., Brewer, W., Desmond, 
P.M., Velakoulis, D., Pantelis, C., 2015. Investigation of orbitofrontal sulcogyral pattern 
in chronic schizophrenia. Psychiatry Res. Neuroimaging.  
Degenhardt, L., Hall, W., Lynskey, M., 2003. Exploring the association between cannabis use 
and depression. Addiction 98, 1493–1504.  
Diekhof, E.K., Falkai, P., Gruber, O., 2008. Functional neuroimaging of reward processing 
and decision-making: A review of aberrant motivational and affective processing in 
addiction and mood disorders. Brain Res. Rev. 59, 164–184.  
Drevets, W.C., 2007. Orbitofrontal cortex function and structure in depression. Ann. N. Y. 
Acad. Sci. 1121, 499–527.  
Elkins, I.J., King, S.M., McGue, M., Iacono, W.G., 2006. Personality traits and the 
development of nicotine, alcohol, and illicit drug disorders: prospective links from 
adolescence to young adulthood. J. Abnorm. Psychol. 115, 26–39.  
European Monitoring Centre for Drugs and Drug Addiction, 2016. European Drug Report 
 21 
2016: Trends and Developments, European Monitoring of Drugs and Drugs Addiction.  
Filbey, F.M., Dunlop, J., 2014. Differential reward network functional connectivity in cannabis 
dependent and non-dependent users. Drug Alcohol Depend. 140, 101–111.  
Filbey, F.M., Yezhuvath, U., 2013. Functional connectivity in inhibitory control networks and 
severity of cannabis use disorder. Am. J. Drug Alcohol Abuse 39, 382–391.  
Frodl, T., Bokde, A.L.W., Scheuerecker, J., Lisiecka, D., Schoepf, V., Hampel, H., Möller, H., 
Brückmann, H., Wiesmann, M., Meisenzahl, E., 2010. Functional connectivity bias of the 
orbitofrontal cortex in drug-free patients with major depression. BPS 67, 161–167.  
Ganella, E.P., Burnett, A., Cheong, J., Thompson, D., Roberts, G., Wood, S., Lee, K., Duff, J., 
Anderson, P.J., Pantelis, C., Doyle, L.W., Bartholomeusz, C., 2015. Abnormalities in 
orbitofrontal cortex gyrification and mental health outcomes in adolescents born 
extremely preterm and/or at an extremely low birth weight. Hum. Brain Mapp. 36, 1138–
1150. 
Hamilton, M., 1960. Hamilton Depression Rating Scale (HDRS). J. Neurol. Neurosurg. 
Psychiatry 23, 56–62.  
Hayes, A.F., 2016. Regression-based statistical mediation and moderation analysis in clinical 
research: Observations, recommendations, and implementation. Invit. Submiss. to 
Behav. Res. Ther. 1–24.  
Hayes, A.F., 2013. Introduction to mediation, moderation, and conditional process analysis: A 
regression-based approach. The Guilford Press, New York. 
Hayes, A.F., 2009. Beyond Baron and Kenny: Statistical mediation analysis in the new 
millennium. Commun. Monogr. 76, 408–420.  
Isomura, S., Hashimoto, R., Nakamura, M., Hirano, Y., Yamashita, F., Jimbo, S., Yamamori, 
H., Fujimoto, M., Yasuda, Y., Mears, R.P., Onitsuka, T., 2017. Altered sulcogyral 
patterns of orbitofrontal cortex in a large cohort of patients with schizophrenia. npj 
Schizophr. 3. doi: 10.1038/s41537-016-0008-y 
Jacobus, J., Castro, N., Squeglia, L.M., Meloy, M.J., Brumback, T., Huestis, M.A., Tapert, 
S.F., 2016. Adolescent cortical thickness pre- and post marijuana and alcohol initiation. 
Neurotoxicol. Teratol. 57, 20–29. 
Klimes-Dougan, B., Garber, J., 2016. Regulatory control and depression in adolescents: 
Findings from neuroimaging and neuropsychological research. J. Clin. Child Adolesc. 
Psychol. 4416, 1–5. 
Kringelbach, M.L., Rolls, E.T., 2004. The functional neuroanatomy of the human orbitofrontal 
cortex: Evidence from neuroimaging and neuropsychology. Prog. Neurobiol. 72, 341–
372. 
Krueger, R.F., 1999. Personality traits in late adolescence predict mental disorders in early 
adulthood: a prospective-epidemiological study. J. Pers. 67, 39–65. 
Kühn, S., Witt, C., Banaschewski, T., Barbot, A., Barker, G.J., Büchel, C., Conrod, P.J., Flor, 
H., Garavan, H., Ittermann, B., Mann, K., Martinot, J.-L., Paus, T., Rietschel, M., 
Smolka, M.N., Ströhle, A., Brühl, R., Schumann, G., Heinz, A., Gallinat, J., 2016. From 
 22 
mother to child: orbitofrontal cortex gyrification and changes of drinking behaviour during 
adolescence. Addict. Biol. 21, 700-708.  
Lacerda, A.L.T., Keshavan, M.S., Hardan, A.Y., Yorbik, O., Brambilla, P., Sassi, R.B., 
Nicoletti, M., Mallinger, A.G., Frank, E., Kupfer, D.J., Soares, J.C., 2004. Anatomic 
evaluation of the orbitofrontal cortex in major depressive disorder. Biol. Psychiatry 55, 
353–358.  
Lavoie, S., Bartholomeuz, C.F., Nelson, B., Lin, A., McGorry, P.D., Velakoulis, D., Whittle, 
S.L., Yung, A.R., Pantelis, C., Wood, S.J., 2014. Sulcogyral pattern and sulcal count of 
the orbitofrontal cortex in individuals at ultra high risk for psychosis. Schizophr. Res. 
154, 93–99.  
Lev-Ran, S., Roerecke, M., Le Foll, B., George, T.P., McKenzie, K., Rehm, J., 2014. The 
association between cannabis use and depression: a systematic review and meta-
analysis of longitudinal studies. Psychol. Med. 44, 797–810.  
Lorenzetti, V., Solowij, N., Yücel, M., 2016. The role of cannabinoids in neuroanatomic 
alterations in cannabis users. Biol. Psychiatry 79, e17–e31.  
Matochik, J.A., Eldreth, D.A., Cadet, J.-L., Bolla, K.I., 2005. Altered brain tissue composition 
in heavy marijuana users. Drug Alcohol Depend. 77, 23–30.  
McRae, K., Gross, J.J., Weber, J., Robertson, E.R., Sokol-Hessner, P., Ray, R.D., Gabrieli, 
J.D.E., Ochsner, K.N., 2012. The development of emotion regulation: An fMRI study of 
cognitive reappraisal in children, adolescents and young adults. Soc. Cogn. Affect. 
Neurosci. 7, 11–22.  
Nakamura, M., Nestor, P.G., Levitt, J.J., Cohen, A.S., Kawashima, T., Shenton, M.E., 
McCarley, R.W., 2008. Orbitofrontal volume deficit in schizophrenia and thought 
disorder. Brain 131, 180–195.  
Nakamura, M., Nestor, P.G., McCarley, R.W., Levitt, J.J., Hsu, L., Kawashima, T., 
Niznikiewicz, M., Shenton, M.E., 2007. Altered orbitofrontal sulcogyral pattern in 
schizophrenia. Brain 130, 693–707. 
Nelson, H.E., 1982. National Adult Reading Test. NFER-Nelson, Windsor, UK. 
Nishikawa, Y., Takahashi, T., Takayanagi, Y., Furuichi, A., Kido, M., Nakamura, M., 
Sasabayashi, D., Noguchi, K., Suzuki, M., 2015. Orbitofrontal sulcogyral pattern and 
olfactory sulcus depth in the schizophrenia spectrum. Eur. Arch. Psychiatry Clin. 
Neurosci.  
Otten, R., Barker, E.D., Maughan, B., Arseneault, L., Engels, R.C.M.E., 2010. Self-control 
and its relation to joint developmental trajectories of cannabis use and depressive mood 
symptoms. Drug Alcohol Depend. 112, 201–208. 
Pagliaccio, D., Barch, D.M., Bogdan, R., Wood, P.K., Lynskey, M.T., Heath, A.C., Agrawal, 
A., 2015. Shared predisposition in the association between cannabis use and 
subcortical brain structure. JAMA Psychiatry 63130, 1–8.  
Schmand, B., Bakker, D., Saan, R., Louman, J., 1991. The Dutch Reading Test for Adults: a 
measure of premorbid intelligence level. Tijdschr. Gerontol. Geriatr. 22, 15–19. 
 23 
Sled, J.G., Zijdenbos, A.P., Evans, A.C., 1998. A nonparametric method for automatic 
correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87–97.  
Solowij, N., Walterfang, M., Lubman, D.I., Whittle, S., Lorenzetti, V., Styner, M., Velakoulis, 
D., Pantelis, C., Yücel, M., 2013. Alteration to hippocampal shape in cannabis users 
with and without schizophrenia. Schizophr. Res. 143, 179–184.  
Stapinski, L.A., Montgomery, A.A., Araya, R., 2016. Anxiety, depression and risk of cannabis 
use: Examining the internalising pathway to use among Chilean adolescents. Drug 
Alcohol Depend. 166, 109–115. 
Takahashi, T., Nakamura, M., Nakamura, Y., Aleksic, B., Kido, M., Sasabayashi, D., 
Takayanagi, Y., Furuichi, A., Nishikawa, Y., Noguchi, K., Ozaki, N., Suzuki, M., 2015. 
The Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain 
neurodevelopmental markers in schizophrenia and healthy subjects. Prog. Neuro-
Psychopharmacology Biol. Psychiatry 56, 11–17. 
Takahashi, T., Nakamura, Y., Nakamura, Y., Aleksic, B., Takayanagi, Y., Furuichi, A., Kido, 
M., Nakamura, M., Sasabayashi, D., Ikeda, M., Noguchi, K., Kaibuchi, K., Iwata, N., 
Ozaki, N., Suzuki, M., 2014. The polymorphism of YWHAE, a gene encoding 14-3-
3epsilon, and orbitofrontal sulcogyral pattern in patients with schizophrenia and healthy 
subjects. Prog. Neuro-Psychopharmacology Biol. Psychiatry 51, 166–171.  
Takayanagi, Y., Takahashi, T., Orikabe, L., Masuda, N., Mozue, Y., Nakamura, K., Kawasaki, 
Y., Itokawa, M., Sato, Y., Yamasue, H., Kasai, K., Okazaki, Y., Suzuki, M., 2010. 
Volume reduction and altered sulco-gyral pattern of the orbitofrontal cortex in first-
episode schizophrenia. Schizophr. Res. 121, 55–65.  
Toro, R., Burnod, Y., 2005. A morphogenetic model for the development of cortical 
convolutions. Cereb. Cortex 15, 1900–1913.  
Tremblay, L., Schultz, W., 1999. Relative reward preference in primate orbitofrontal cortex. 
Nature 398, 704–708.  
Uehara-Aoyama, K., Nakamura, M., Asami, T., Yoshida, T., Hayano, F., Roppongi, T., 
Fujiwara, A., Inoue, T., Shenton, M.E., Hirayasu, Y., 2011. Sexually dimorphic 
distribution of orbitofrontal sulcogyral pattern in schizophrenia. Psychiatry Clin. 
Neurosci. 65, 483–489.  
United Nations Office on Drugs and Crime, 2015. World drug report 2015. United Nations 
publication, Sales No. E.15.XI.6.  
Verdejo-García, A., Rivas-Pérez, C., Vilar-López, R., Pérez-García, M., 2007. Strategic self-
regulation, decision-making and emotion processing in poly-substance abusers in their 
first year of abstinence. Drug Alcohol Depend. 86, 139–146.  
Volkow, N.D., Fowler, J.S., 2000. Addiction, a disease of compulsion and drive: involvement 
of the orbitofrontal cortex. Cereb. Cortex 10, 318–325.  
Wagner, D.D., Altman, M., Boswell, R.G., Kelley, W.M., Heatherton, T.F., 2013a. Self-
regulatory depletion enhances neural responses to rewards and impairs top-down 
control. Psychol. Sci. 24, 2262–2271.  
 24 
Wagner, D.D., Altman, M., Boswell, R.G., Kelley, W.M., Heatherton, T.F., 2013b. Self-
regulatory depletion enhances neural responses to rewards and impairstop-down 
control. Psychol. Sci. 24, 2262–2271.  
Watanabe, H., Nakamura, M., Ohno, T., Itahashi, T., Tanaka, E., Ohta, H., Yamada, T., 
Kanai, C., Iwanami, A., Kato, N., Hashimoto, R., 2014. Altered orbitofrontal sulcogyral 
patterns in adult males with high-functioning autism spectrum disorders. Soc. Cogn. 
Affect. Neurosci. 9, 520–528. 
Wechsler, D., 1999. Wechsler Abbreviated Scale of Intelligence (WASI) Manual. 
Psychological Corporation, San Antonio, TX. 
Wechsler, D., 1997. WAIS-III administration and scoring manual. The Psychological 
Corporation, San Antonio, TX. 
White, T., Su, S., Schmidt, M., Kao, C.Y., Sapiro, G., 2010. The development of gyrification in 
childhood and adolescence. Brain Cogn. 72, 36–45.  
Whittle, S., Bartholomeusz, C., Yücel, M., Dennison, M., Vijayakumar, N., Allen, N.B., 2014. 
Orbitofrontal sulcogyral patterns are related to temperamental risk for psychopathology. 
Soc. Cogn. Affect. Neurosci. 9, 232–239.  
Ystrom, E., Reichborn-Kjennerud, T., Neale, M.C., Kendler, K.S., 2014. Genetic and 
environmental risk factors for illicit substance use and use disorders: Joint analysis of 
self and co-twin ratings. Behav. Genet. 44, 1–13. 
Yücel, M., Lorenzetti, V., Suo, C., Zalesky, A., Fornito, A., Takagi, M.J., Lubman, D.I., Solowij, 
N., 2016. Hippocampal harms, protection and recovery following regular cannabis use. 
Transl. Psychiatry 6, e710.  
Yücel, M., Solowij, N., Respondek, C., Whittle, S., Fornito, A., Pantelis, C., Lubman, D.I., 
2008. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. 
Gen. Psychiatry 65, 694–701. 
Zheng, W., Chee, M.W.L., Zagorodnov, V., 2009. NeuroImage improvement of brain 
segmentation accuracy by optimizing non-uniformity correction using N3. Neuroimage 
48, 73–83.  
Zilles, K., Schleicher, A., Langemann, C., Amunts, K., Morosan, P., Palomero-Gallagher, N., 
Schormann, T., Mohlberg, H., Bürgel, U., Steinmetz, H., Schlaug, G., Roland, P.E., 
1997. Quantitative analysis of sulci in the human cerebral cortex: Development, regional 
heterogeneity, gender difference, asymmetry, intersubject variability and cortical 
architecture. Hum. Brain Mapp. 5, 218–221.  
Zimmerman, M., Chelminski, I., Posternak, M., 2004. A review of studies of the Hamilton 
Depression Rating Scale in healthy controls. J. Nerv. Ment. Dis. 192, 595–601.  
 
